Molecular Mechanisms of Primary Hyperparathyroidism

Reviews in Endocrine and Metabolic Disorders

Volumn 1, Issue 4, 2000, Pages 297-305

  Hendy, Geoffrey N ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Clonality; Primary hyperparathyroidism; Proto oncogene; Tumor suppressor; Tumorigenesis

Indexed keywords

ANIMAL; GENETICS; HUMAN; HYPERPARATHYROIDISM; PARATHYROID TUMOR; PATHOLOGY; REVIEW;

ANIMALS; HUMANS; HYPERPARATHYROIDISM; PARATHYROID NEOPLASMS;

EID: 0034329531     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026518502081     Document Type: Article

References (71)

1. Fialkow PJ, Jackson CE, Block MA, Greenwald KA. Multicellular origin of parathyroid "adenomas". N Eng J Med 1977;277:696-698.
2. Jackson CE, Cerny JC, Block MA, Fialkow PJ. Probable clonal origin of aldosteronomas vs. multicellular origins of parathyroid "adenomas". Surgery 1982;875:875-879.
3. Arnold A, Staunton CE, Kim HG, Gaz RD, Kronenberg HM. Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Eng J Med 1988;318:658-662.
4. Cryns VL, Thor A, Xu H-J, Hu S-X, Wierman ME, Vickery AL, Benedict WF, Arnold A. Loss of the retinoblastoma tumor suppressor gene in parathyroid carcinoma. N Eng J Med 1994;330:757-761.
5. Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, James LA, Goldsmith PK, Saggar SK, Park SY, Spiegel AM, Burns AL, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Emmert-Buck MR, Guru SC, Manickam P, Crabtree J, Erdos MR, Collins FS, Chandrasekharappa SC. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res 1999;5:397-439.
6. Pannett AAJ, Thakker RV. Multiple endocrine neoplasia type 1. Endocrine-related Cancer 1999;6:449-473.
7. Arnold A, Brown M, Urena P, Gaz RD, Sarfati E, Drueke T. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95:2047-2053.
8. Farnebo F, Farnebo L, Nordenstrom J, Larsson C. Allelic loss on chromosome 11 is uncommon in parathyroid glands of patients with hypercalcaemic secondary hyperparathyroidism. Europ J Surg 1997;163:331-337.
9. Arnold A. Genetic basis of endocrine disease. 5: Molecular genetics of parathyroid gland neoplasia. J Clin Endocrinol Metab 1993;77:1108-1112.
10. Hsi E, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996;81:1736-1739.
11. Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, Yamada K, Numano M, Tanaka Y, Takagi H. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure vs. primary adenoma. Kid Int 1999;55:1375-1383.
12. Vasef MA, Brynes R, Sturm M, Bromley C, Robinson RA. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Path 1999;12:412-416.
13. Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosom Cancer 1998;22:66-71.
14. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bell-linked candidate oncogene. Nature 1991;350:512-515.
15. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocrine Rev 1999;20:501-534.
16. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 1998;83:1766-1770.
17. Farnebo F, Kytola S, Teh BT, Dwight T, Wong FK, Hoog A, Elvius M, Wassif WS, Thompson NW, Farnebo LO, Sandelin K, Larsson C. Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol Metab 1999;84:3775-3780.
18. Agarwal SK, Schrock E, Kester MB, Burns AL, Heffess CS, Ried T, Marx SJ. Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet 1998;106:30-36.
19. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome II and is lost in insulinoma. Nature 1988;332:85-87.
20. Cryns VL, Yi SM, Tahara H, Gaz RD, Arnold A. Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosom. Cancer 1995;13:9-17.
21. Williamson C, Pannett A, Pang JT, Wooding C, McCarthy M, Sheppard MN, Monson JP, Clayton RN, Thakker RV. Localization of a gene causing endocrine neoplasia to a 4 cM region on chromosome 1p35-p36. J Med Genet 1997;34:617-619.
22. Tahara H, Smith AP, Gaz RD, Zariwala M, Xiong Y, Arnold A. Parathyroid tumor suppressor on 1p: analysis of the p18 cyclin-dependent kinase inhibitor gene as a candidate. J Bone Miner Res 1997;12:1330-1334.
23. Tahara H, Smith A, Gaz RD, Cryns VL, Arnold A. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 1996;56:599-605.
24. Tahara H, Smith AP, Gaz RD, Arnold A. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. J Clin Endocrinol Metab 1996;81:3663-3667.
25. Inagaki C, Dousseau M, Pacher N, Sarfati E, Drueke TB, Gogusev J. Structural analysis of gene marker loci on chromosomes 10 and 11 in primary and secondary uraemic hyperparathyroidism. Nephrol Dial Transplant 1998;13:350-357.
26. Friedman E, Bale AE, Marx SJ, Norton JA, Arnold A, Tu T, Aurbach GD, Spiegel AM. Genetic abnormalities in sporadic adenomas. J Clin Endocrin Metab 1990;71:293-297.
27. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res 1992;52:5061-5064.
28. Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 1994a;78:1320-1324.
29. Hakim JP, Levine MA. Absence of p53 point mutations in parathyroid adenoma and carcinoma. J Clin Endocrinol Metab 1994;78:103-106.
30. Orndal C, Johansson M, Heim S, Mandahl N, Mansson B, Alumets J, Mitelman F. Parathyroid adenoma with t(1:5) (p22:q32) as the sole clonal chromosomal abnormality. Cancer Genet Cytogenet 1990;48:225-228.
31. Carling T, Imanishi Y, Gaz RD, Arnold A. RAD51 as a candidate parathyroid tumor suppressor gene on chromosome 15q: absence of somatic mutations. Clin Endocrinol 1999a;51:403-407.
32. Carling T, Imanishi Y, Gaz RD, Arnold A. Analysis of the RAD54 gene on chromosome 1p as a potential tumor-suppressor gene in parathyroid adenomas. Int J Cancer 1999b;83:80-82.
33. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-407.
34. The European Consortium on MEN1. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet 1997;6:1177-1183.
35. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FC, Chandrasekharappa SC. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 1998;95:1630-1634.
36. Kaji H, Canaff L, Goltzman D, Hendy GN. Cell cycle regulation of menin expression. Cancer Res 1999;59:5097-5101.
37. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL. Menin interacts with the API transcription factor JunD and represses JunD-activated transcription. Cell 1999;96:143-152.
38. Kim YS, Burns AL, Goldsmith PK, Heppner C, Park SY, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ. Stable overexpression of MEN1 suppresses tumorigenicity of RAS. Oncogene 1999;18:5936-5942.
39. Mulligan LM, Kwok JBJ, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458-460.
40. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-856.
41. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HKP, Lips CJM, Nishisho I, Takai S-I, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjöld M, Komminoth P, Hendy GN, Gharib H, Thibodeau SN, Lacroix A, Frilling A, Ponder BAJ, Mulligan LM. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 1996;276:1575-1579.
42. Pausova Z, Soliman E, Amizuka N, Janicic N, Konrad EM, Arnold A, Goltzman D, Hendy GN. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1996;81:2711-2718.
43. Al Kawas S, Bolivar I, Canaff L, Hendy GN, Goltzman D. Cell-specific expression of the RET receptor tyrosine kinase, and its ligand in normal, hyperplastic and adenomatous parathyroid glands. Bone 1998;23S:S568.
44. Marsh DJ, Zheng Z, Arnold A, Andrew SD, Learoyd D, Frilling A, Komminoth P, Neumann HP, Ponder BA, Rollins BJ, Shapiro GI, Robinson BG, Mulligan LM, Eng C. Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for a RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1997;82:3025-3028.
45. Marx SJ, Attie MF, Levine MA, Spiegel AM, Downs RW, Lasker RD. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine 1981;60:397-412.
46. Law Jr WM, Heath III H. Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenic studies in 21 families. Ann Intern Med 1985;102:511-519.
47. Janicic N, Soliman E, Pausova Z, Seldin MF, Riviere M, Szpirer J, Szpirer C, Hendy GN. Mapping of the calcium-sensing receptor to human chromosome 3q13.3-21 by fluorescence in situ hybridization, and localization to rat chromosome 11 and mouse chromosome 16. Mammalian Genome 1995;6:798-801.
48. 2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993;75:1297-1303.
49. 2+-sensing receptor gene in familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT). Amer J Hum Genet 1995;56:880-886.
50. Pearce SHS, Trump D, Wooding C, Besser GM, Chew SL, Grant DB, Heath DA, Hughes IA, Paterson CR, Whyte MP, Thakker RV. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. 1995;96:2683-2692.
51. Heath III H, Odelberg S, Jackson CE, Teh BT, Hayward N, Larsson C, Buist NRM, Krapcho KJ, Hung BC, Capuano IV, Garrett JE, Leppert MF. Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. J Clin Endocrinol Metab 1996;81:1312-1317.
52. Pollak MR, Chou YHW, Marx SJ, Steinmann B, Cole DEC, Brandi ML, Papapoulos SE, Menko FH, Hendy GN, Brown EM, Seidman CE, Seidman JG. Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype. J Clin Invest 1994;93:1108-1112.
53. Thompson DB, Samowitz WS, Odelberg S, Davis RK, Szabo J, Heath III H. Genetic abnormalities in sporadic parathyroid adenomas: loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus. J Clin Endocr Metab 1995;80:3377-3380.
54. 2+-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab 1995;80:3107-3110.
55. Cetani F, Pinchera A, Pardi E, Cianferotti L, Vignali E, Picone E, Miccoli P, Viacava P, Marcocci C. No evidence for mutations in the calcium-sensing receptor gene in sporadic parathyroid adenomas. J Bone Miner Res 1999;14:878-882.
56. 2+-sensing receptor in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598-1606.
57. Farnebo F, Enberg U, Grimelius L, Backdahl M, Schalling M, Larsson C, Farnebo LO. Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J Clin Endocrinol Metab 1997;82:3481-3486.
58. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kid Int 1997;51:328-336.
59. Parfitt AM. Parathyroid growth, normal and abnormal. In: Bilezekian J.P., Marcus R., Levine M.A., eds. The parathyroids. New York: Raven Press, 1994:373-405.
60. Szabo J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, Chew SL, Besser GM, Thakker RV, Huff V, Leppert MF, Heath III H. Hereditary hyperparathyroidism-jaw syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 1995;56:944-950.
61. Wassif WS, Farnebo F, Teh BT, Moniz CF, Li FY, Harrison JD, Peters TJ, Larsson C, Harris P. Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clin. Endocrinol 1999;50:191-196.
62. Teh BT, Farnebo F, Twigg S, Hood S, Kytola S, Korpi-Hyovalti E, Wong FK, Nordenstrom J, Grimelius L, Sandelin K, Robinson B, Farnebo LO, Larsson C. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 1998;83:2114-2120.
63. Williamson C, Cavaco BM, Jausch A, Dixon PH, Forbes S, Harding B, Holtgreve-Grez H, Schoell B, Pereira MC, Font AP, Loureiro MM, Sobrinho LG, Santos MA, Thakker RV. Mapping the gene causing hereditary primary hyperparathyroidism in a Portuguese kindred to chromosome 1q22-q31. JBone Miner Res 1999;14:230-239.
64. Kassem M, Zhang X, Brask S, Eriksen EF, Mosekilde L, Kruse T. Familial isolated primary hyperparathyroidism. Clinical Endocrinology 1994;41:415-420.
65. Teh BT, Esapa C, Houlston R, Grandell U, Farnebo F, Nordenskjold M, Pearce CJ, Carmichael D, Larsson C, Harris PE. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am J Hum Genet 1998;63:1544-1549.
66. Dotzenrath C, Teh BT, Farnebo F, Cupisti K, Svensson A, Toell A, Goretzki P, Larsson C. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 1996;81:3194-3196.
67. Hendy GN, Kronenberg HM, Potts Jr JT, Rich A. Nucleotide sequence of cloned cDNAs encoding human preproparathyroid hormone. Proc Natl Acad Sci USA 1981;78:7365-7369.
68. Vasicek TJ, McDevitt BE, Freeman MW, Fennick BJ, Hendy GN, Potts Jr JT, Rich A, Kronenberg HM. Nucleotide sequence of the human parathyroid hormone gene. Proc. Natl. Acad. Sci. USA 1983;80:2127-2131.
69. Yoshimoto K, Yamasaki R, Sakai H, Tezuka U, Takahashi M, lizuka M, Sekiya T, Saito S. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 1989;68:976-981.
70. Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 1990;323:1324-1328.
71. Strewler GJ, Budayr AA, Clark OH, Nissenson RA. Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. J Clin Endocrinol Metab 1993;76:1373-1375.